GlassScriptPhysician profile
Virginia Gaulden
NPI 1942962956
$694.80
in general payments reported to CMS, 2019-2025
15 companies · $294 in 2025
The $294 reported for 2025 was more than what 89% of Advanced Practice Midwife providers received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $81.02 · 2023: $168 · 2024: $152 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $613.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $156.57 | 2025 | Aptima, Fetal Fibronectin Enzyme Immunoassay |
| Organon LLC | $88.95 | 2024-2025 | Jada System |
| Exact Sciences Corporation | $82.60 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $74.44 | 2022-2024 | |
| Astellas Pharma US INC | $54.68 | 2023-2025 | Veozah |
| Daiichi Sankyo INC. | $47.38 | 2022-2023 | Injectafer |
| Boston Scientific Corporation | $29.71 | 2025 | Solyx Sis System |
| Mayne Pharma Commercial LLC | $29.60 | 2025 | |
| Convatec INC. | $27.92 | 2025 | |
| Mylan Pharmaceuticals INC. | $22.08 | 2022 | |
| Novo Nordisk INC | $20.06 | 2024 | Wegovy |
| Sage Therapeutics, LLC | $17.63 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.80 | 2022 | |
| Pfizer INC. | $13.35 | 2023 | |
| Shield Therapeutics INC | $13.03 | 2023 | Accrufer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Gaulden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.